Overview

A Study in Japanese Participants With Moderate-to-Severe Psoriasis

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab